*These authors contributed equally to this work. Spinocerebellar ataxia type 12 (SCA12) is a rare neurodegenerative disorder caused by CAG repeat expansion in the PPP2R2B gene. Previously, the causal length of CAG repeats ascribed to SCA12 was more than 51; however, a few reports have also described unusual occurrence of CAG repeat length 36-51 repeats among patients of different geographical population, with atypical clinical association. From our systematic search for SCA12 in a genetic screening programme, we have identified a large number of SCA12 cases. In this study, we specifically describe the clinical behaviour of 18 patients who harbour CAG repeats in the range of 43-50 and compare their clinical behaviour with patients carrying typical pathogenic threshold length of 51 CAG repeats. Unsurprisingly, we observed that the clinical characteristics were similar to those of typical SCA12 phenotype, with large variability in the age at onset. Radiologically, we observed a variable degree of cerebro-cerebellar degeneration along with white matter changes that do not correlate with the disease severity. We define a new pathogenic threshold of CAG-43 to be pathogenic for SCA12 diagnosis and also describe the clinical profiles of two biallelic CAG expansion carriers. We also propose that SCA12 might not be that restricted in terms of occurrence in other geographical or ethnic populations, as it was previously presumed to be. 
Introduction
Spinocerebellar ataxia type 12 (SCA12) is a late onset autosomal dominant neurodegenerative disorder. Phenotypically, at disease onset, SCA12 manifests characteristic action tremors in the upper limbs, followed mainly by other movement abnormalities i.e. head tremor, dysarthria, and later during the course of disease progression, patients often develop gait ataxia (Holmes et al., 2001; Srivastava et al., 2001) . Among other neurological deficits, pyramidal features, extrapyramidal abnormalities, chorea, dementia and cognitive declines have also been reported (Srivastava et al., 2001) . The disease exhibits inter/intra familial phenotypic heterogeneity (Holmes et al., 2001 ). Brain imaging usually reveals both cerebral and cerebellar atrophy with relative sparing of brainstem, thalamus, basal ganglia and other subcortical brain regions (Holmes et al., 2003) . The age at disease onset is highly variable and ranges from 8-62 years, with the mean age of onset being 38 years (Holmes et al., 2001) . The causal mutation for SCA12 is the expansion of CAG repeats (451 repeat units) in the 5'UTR of PPP2R2B gene (Holmes et al., 1999) . It is the second most common dominant ataxia in North India and almost uniquely observed in the Indian population. However, there are reports of SCA12 occurrence outside the Indian subcontinent as well: USA (the original family of American kindred with German descent in whom SCA12 was first described), Italy and the Chinese (Han) population (Holmes et al., 1999; Jiang et al., 2005; Brussino et al., 2010; Li et al., 2011) . To date, the reported and clear pathological range for CAG repeats has been found to be 51-78 (Holmes et al., 2001; Srivastava et al., 2001; Bahl et al., 2005) , although there has been a recent report of identification of CAG-46 as the shortest pathogenic allele in PPP2R2B (Dong et al., 2015) . The unambiguous normal range of PPP2R2B-CAG has been found to be 4-31 repeats (Fujigasaki et al., 2001; Srivastava et al., 2001; Sulek et al., 2004; Sulek-Piatkowska et al., 2010; O'Hearn et al., 2012; Merrill, 2012) . From the earlier reports, concerns have remained regarding the cut-off pathogenic length for CAG repeats that are associated with SCA12 phenotype, namely (i) observation of two patients with late onset ataxia carrying 40 and 41 CAG repeats from the German population (Hellenbroich et al., 2004) ; (ii) observation of 36 and 43 repeats in ataxic patients from the Czech population (Musova et al., 2013) ; (iii) observation of one asymptomatic individual with 45 CAG repeats in the Indian population (Fujigasaki et al., 2001) ; (iv) observation of 49 CAG alleles in a patient with phenotype of Creutzfeldt-Jacob Disease (CJD) (Hellenbroich et al., 2004) ; and (v) the observation of CAG repeats 51 and 52 in Iranian patients with bipolar disorder (O'Hearn et al., 2012) . In this study, we report the clinical profiles of SCA12 patients with low abnormal CAG repeat length (CAG551) and compare their features with the patient group with defined minimum pathogenic length of CAG-51. This study provides the definition of minimum pathogenic CAG allele causal for SCA12 phenotype and indicates the plausible pathogenic role of earlier reported low/ intermediate CAG repeats in the range of 43-49 among ataxic patients from various global populations.
Materials and methods
The patients carrying PPP2R2B-CAG 4 51 (n = 27 from 25 families) were identified from the SCA12 patient group from our large scale effort for phenotype-genotype correlation in 125 unrelated SCA12 families. General demographics of these unrelated 124 index cases were as follows with mean (standard deviation, SD) and range for PPP2R2B-CAG expansion 56.5 (5.7), 43-73; age at onset [47 (10. ] and nine unrelated patients who were carriers of typical pathogenic threshold repeat length CAG (51) for SCA12. All the patients had manifestations of SCA12-like phenotype prior to genetic investigations (familial late onset progressive action tremor in hands and/or tremulous speech and/or head tremor and/or gait ataxia at the onset of disease and variable association of other neurological manifestations). Except for one patient, all others had a background of ethnicity as described earlier for SCA12 [an endogamous population from Haryana state of Northern India, IE-N-LP18 as described in the Indian Genome Variation Consortium (IGV) consortium study (2008) ].
Clinical analysis included standard neurological examination of all probands and affected relatives by a team of neurologists. A detailed and comparative radiological investigation of brain was performed using images from 1.5 T MRI for patients harbouring different CAG alleles. Assessment of atrophic/degenerative pattern was evaluated using Koedam scores for parietal atrophy (Koedam et al., 2011) , medial temporal lobe atrophy (MTA) scale (Heo et al., 2013) , Fazekas scale for white matter lesions (Leaper et al., 2001) , global cortical atrophy (GCA) scale and cerebellar atrophy by visual assessment. Molecular analysis for the PPP2R2B-CAG repeat length estimation was done using fluorescence-based polymerase chain reaction (PCR) amplification with previously published primers (Srivastava et al., 2001; Bahl et al., 2005) . The amplified fluorescent labelled PCR products were analysed by capillary electrophoresis on 3130xl ABI sequencer (Applied Biosystems). The sizing analysis for CAG length estimation was carried out by fragment analysis tool in GeneMapper Õ software v.4 (ABI). The confirmation of CAG repeat length was carried out by Sanger sequencing method by PCR using unlabelled primers (as previously described), followed by direct sequencing using ABI BigDye Õ chain terminator sequencing kit. We also later approached (by house visit) 11 other affected and unaffected siblings of the six kindreds (with CAG 43-50) for clinical and genetic assessment. All of the recruited patients had given their informed consent for participation in this study and the study was approved by the Institutional Ethics committees of the participating institutes.
Results
The general demographic details were as follows: the patient group with intermediate pathogenic CAG alleles (IpA, (43) (44) (45) (46) (47) (48) (49) (50) 54.11 (9.9, ; (ii) neurological features: tremor and cerebellar ataxia were observed in near similar frequencies between the two groups; Babinski sign, nystagmus, dysarthria and urinary symptoms were observed with statistically non-significant higher frequency in the IpA group. However, in comparison with the earlier description by Srivastava et al. (2001) (patients with CAG range 56-69), the frequencies of various neurological signs were lower in both the IpA and PA groups. We observed a wide heterogeneity in the age at onset among patients harbouring the same repeat length, for CAG-45 (57-61 years), CAG-46 (51-67 years), CAG-47 (50-65 years), , and . Similar to that of the PA group, we observed that in the IpA group, the most common symptom at onset was action tremor in the hand (55.5%) and if tremor were considered irrespective of anatomical location (including speech and head tremor) then it remains as a symptom at onset in 77% of the cases. Upper limb incoordination was observed as a symptom at onset in one individual and walking imbalance in the rest of the patients. However, frequencies observed were quite similar to those described earlier (67%) and those observed in patients with CAG-51 (67%). In 50% of the patients with CAG-51 or CAG551, tremor at its onset was asymmetric affecting either side unequally as per history. However, on examination, the severity observed was symmetric in most of the patients. All patients had hand tremor and/or gait ataxia on examination, except for one patient (Patient AT392/3905, Table  1 ), who, with CAG-16/47 and disease duration of 4 years, did not develop any other deficit except for head tremor. A general pattern of evolution of symptoms was tremor, followed by ataxia and speech slurring/tremor. Gait ataxia developed 1-5 years later after the onset of tremor (median 2 years). In addition, a weak negative correlation (statistically non-significant) was observed between CAG length and the age at onset (Pearson correlation coefficient r = À0.271). However, an extended analysis in our larger cohort of 124 unrelated patients with SCA12 showed a statistically significant correlation between CAG repeats and age at onset with the following values, Pearson's r (À0.65), P-value 5 10 À4 .
Association of 43 CAG repeats with SCA12 phenotype
The proband of a three-generation pedigree (Fig. 1 , Pedigree 872), was a 74-year-old female (Patient AT2058), who presented with asymmetric onset of tremor in the right hand, writing difficulty for the previous 2 years and developed gait ataxia a year later after tremor onset. Neurological examination revealed normal higher mental functions (normal Mini-Mental State Examination), finger-nose test showed gross dysmetria and tandem gait was impaired. Although the patient could still walk without support, her gait was clearly abnormal and irregular. Eye signs were normal except for broken pursuits. The patient had a moderate degree of bradykinesia. Deep tendon reflexes were normal except for reduced ankle jerk. Sensory examination revealed decreased vibration sense in lower limb (LL) 4 upper limb (UL). No extrapyramidal features, no fasciculations and no muscle atrophy were present. MRI brain scan showed both cerebral and cerebellar atrophy ( Fig. 2A-C ). Sensory and motor nerve conduction studies were normal. A total score of 15 was obtained on the ataxia severity rating scale. Regular follow-up (2011-15) showed progressively increasing disease and severity scores assessed by the International Cooperative Ataxia Rating Scale (ICARS). Her family history was positive for tremor/ataxia in multiple individuals (Fig. 1, Pedigree 872) . Among other members of the family who were available for genetic and clinical analysis, two affected siblings (Patients AT894 and AT2059) were also study subjects (Table 1) . We later analysed three unaffected individuals of this family by house visit, for clinical assessment and genetic analysis. Three of the asymptomatic individuals had no neurological manifestation and their genetic analysis revealed CAG repeats 14/39 for Patient AT4388 (age 89 years) and Patient AT4389 (age 82 years). The remaining sibling Patient AT4387 (age 77 years) was found to be a carrier of 17/39 CAG genotype (Fig. 1 , Pedigree AT872).
Effect of biallelic CAG repeat expansion on SCA12 phenotype
We identified two individuals with biallelic expansion, one of whom (Patient AT476/1498) harboured 45/45 CAG alleles and the other carried a CAG-42/51 genotype (Patient AT648/2017) (Fig. 1, Pedigree AT648 ). The latter case (CAG-42/51) was a 55-year-old female who had developed A-T190-
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Male:Female ratio progressive asymmetric hand tremors (right 4 left) over the past 5 years and gait ataxia for 3 years. Nystagmus, broken pursuits, hyperreflexia and Babinski sign were observed and she had a moderate degree of intention tremor and gait ataxia on examination. Radiologically, no obvious atrophic changes were observed in the MRI brain scan. The proband had a strong family history (Fig. 1 Table 1 ). Patient AT476/1498 had disease onset at 61 years with tremulous speech as the onset symptom, while the heterozygous individuals with CAG-45 had age of onset at 57 and 60 years, respectively. The disease severity analysed using ICARS for Patient AT630/1683 was 35 with 3 years of disease duration, whereas, the 45/45 homozygous subject had a comparable severity score of 27 with 2 years of disease duration.
Radiological findings
In general, the brain MRI findings of patients showed patterns of variable degree of cortical atrophy and cerebellar atrophy in both groups of patients (IpA or PA); however, cortical atrophy was more pronounced than cerebellar atrophy. We also comparatively analysed the MRI images of patients carrying different CAG length 43-51 using visual assessment and standard scoring tools ( Fig. 2 and Table 2 ). We observed that on every applied scale for assessment of atrophic changes, except for two patients, all showed some varying degree (mild-to-moderate) of cortical atrophy greater than cerebellar atrophy ( Table  2) . The two patients, who interestingly harbour typical pathogenic lengths CAG-51 (Patient AT1358) and biallelic expansion 42/51 (Patient AT648/2017) and disease duration of 2 and 5 years, respectively, did not show any atrophic changes in either the cortical or cerebellar region. For other patients from the IpA group, we found that there was no correlation with disease severity or disease duration and atrophic changes in the brain. Unexpectedly, a 74-year-old patient (Patient AT872/AT2058) with the lowest abnormal CAG-43 expansion, showed a moderate degree of cortico-cerebellar atrophy, probably reflecting contribution of age-related changes in the brain in final radiological interpretation. We also observed white matter lesions in four patients (Patients AT476/1498, AT872/AT2058, AT1403/ 2800 and AT3500/4301) on the Fazekas scale, with prominent T 2 white matter hyperintensities (WMHs) in bilateral middle and superior cerebellar peduncle (Patient AT872/AT2058; CAG-14/43 and Patient AT630/1683; CAG-13/45) and additional WMHs in dorsal tegmentum in Patient AT630/1683.
Discussion
Certain spinocerebellar ataxia subtypes caused by triplet/ tandem repeat expansion exhibit a differential prevalence with respect to ethnic and geographical background, mainly due to founder mutations for specific SCA loci (Duenas et al., 2006) . Globally, apart from some common SCA subtypes (SCA1-3), few ataxia subtypes have a population-specific over-representation e.g. SCA10 in Brazil and Mexico, DRPLA in Japan and SCA12 in India (Duenas et al., 2006; Faruq et al., 2009) . In India, SCA12 is mostly confined to one endogamous population; however, $5-8% of families with SCA12 have been found from other ethnic communities (unpublished observation from our SCA patient cohort). Clinically, the SCA12 phenotype has a unique manifestation of prominent action tremor of hands, which distinguishes it from other SCA subtypes. It does, however, resemble the phenotype of Fragile X-associated tremor/ataxia syndrome (FXTAS) (Faruq et al., 2014) . Atypical neurological presentations including bipolar psychiatric disease and amyotrophic lateral sclerosis have been associated with PPP2R2B-CAG expansion (both pathogenic and intermediate length CAG repeats) (Hellenbroich et al., 2004; O'Hearn et al., 2012; Musova et al., 2013) . In this study, we aimed to identify the clinical and genetic behaviour of patients who were initially ascribed a clinical diagnosis for SCA12 and were later identified as carrying varying lengths of CAG repeats in the PPP2R2B gene in the range of 43-50 (n = 18), which we refer to as intermediate length pathogenic repeats (IpA).
We then compared their features with patients who harboured minimum definitive pathogenic length alleles (PA, CAG-51, n = 9) in order to understand the relevance of intermediate CAG length with respect to typical SCA12 phenotype. We observed that in the IpA group of patients, the mean age at onset was 58 years (with a wide range, 35-72 years) with no clear correlation with CAG length, which is contrary to the observed negative correlation of CAG and age and onset in the larger dataset of SCA12 patients (n = 124). Hence, other factors may have a significant contribution towards the age at onset in the IpA patient group. However, irrespective of age at disease onset, the phenotypes show typical features of SCA12. The clinical and genetic features in one kindred (Patient AT872) were of particular interest, where the proband and her two siblings with typical SCA12 phenotype carried varying CAG lengths, 43, 47 and 49. None of the three unaffected siblings (neurologically normal at older age than proband's age) carried these repeat lengths and interestingly were all heterozygous carriers of 39 repeats. Thus, with the proband with CAG-43 repeats (Patient AT872/2058, age at onset 72 years) with observed clinical features suggestive of typical SCA12 phenotype as also indicated by radiological manifestations and the absence of any SCA12 features in CAG-39 repeat carriers, it is likely that 43-CAG is the minimum pathogenic length for the SCA12 phenotype in this family. In addition, we would like to mention that the previously reported ataxia patients with CAG repeats in the range of 36 and 43 repeats from the Czech population were younger in age than our proband (Musova et al., 2013) . They may not have manifested the typical SCA12 phenotype at that age or presented with atypical features of SCA12. Other than this, from a molecular biology point of view, it has also previously been shown that expanded CAG repeats (with sequence context), when placed in the promoter region of a luciferase reporter, enhance luciferase activity in a length-dependent manner (Lin et al., 2010; O'Hearn et al., 2015) . That study also showed that CAG length of 35 as minimum can increase luciferase reporter activity at a transcriptional level. Thus, taking all this evidence into account, we consider that CAG-43 repeats can lead to molecular pathological events resulting in neurodegeneration and can be considered as the shortest pathogenic length for the SCA12 phenotype. We also agree that more evidence will be necessary to observe the phenotypic variability associated with CAG-43 or incomplete penetrance.
Other than CAG-43, we tried to analyse other CAG IpA (45-50) in the available family members of the respective kindreds (n = 6). In a kindred with heterozygous CAG-45 (Patient AT1005) (Supplementary material), the asymptomatic sibling (age 63 years) had CAG-42. Another kindred (AT3500) with index patient (heterozygous CAG-47) had two other affected siblings (twins) who were found to have CAG-46 and CAG-47 with age of disease onset at 63 and 62 years, respectively. For four other kindreds, CAG repeat size data were available for offspring (who were recruited as a part of presymptomatic testing). However, having their asymptomatic status and younger age, these individuals will not be suitable for studying the incomplete penetrance (Supplementary material). We can therefore state that, the previously described Indian subject with heterozygous CAG-45 may develop disease at a later point, as we noted large heterogeneity in the age at onset of our SCA12 patients with CAG-45 and other intermediate alleles. The cases described in the German population who were found to carry 40 and 41 CAG repeats (Hellenbroich et al., 2004) and were also shown to manifest late onset ataxias, may also have pathogenic significance in the context of SCA12 as shown that luciferase activity is enhanced by a minimum of 35 CAG repeats. In the present study cohort, we also observed a presymptomatic individual, a 28-year-old female (Patient AT2105), who carried CAG 9/42 (Fig. 1 , Pedigree 648) and had manifested tremor upon objective assessment, which will require follow-up to confirm its pathogenicity. We also observed that SCA12 biallelic CAG expansion exerts no added clinical severity or phenotypic modulation. It has also been observed in other triplet repeat expansion disease cases that homozygosity may or may not influence overall severity, which is contrary to the hypothesis of toxic accumulation of RNA or protein species in the form of inclusion and its role as a key governing mechanism of neurodegeneration in triplet repeat disorders (Duenas et al., 2006) .
The radiological findings are suggestive of clinical or subclinical manifestations of diffuse degenerative programme in the brain of patients harbouring CAG 43-50, showing no clear correlation with phenotypic manifestations. The findings corroborate with neuropathological changes as reported by a post-mortem study of brain tissue, where mild cerebellar atrophy was observed as compared to the cerebral cortical atrophy (O'Hearn et al., 2015) . We also observed white matter changes in neural connections (superior and middle cerebellar peduncles) of cerebellum in two MRIs. Two reports documented MRI white matter abnormalities (white matter changes in the cerebral cortex) and another showed reduced fractional anisotropy in cerebral cortex and cerebellar vermis in patients and presymptomatic subjects (Li et al., 2014; Hu et al., 2015) . Radiologically, no gross relation was observed with clinical manifestations in our patients, but based on reported literature and our findings, it can be speculated that tremor and ataxia symptoms are initial and 'tip of the iceberg' features of major pathological changes, which would evolve with disease course. Grossly, cerebellum appears to be less involved at least in its cortical areas as also observed in a pathological study; however, more evidence is needed to understand the microstructural changes in the brain of SCA12 patients, reflected as clinical findings. It can also be speculated that cerebellar degeneration may be representative of secondary changes as to primary degeneration affecting cerebral cortex and its connection to cerebellum. To date, no evidence is available to document the tremorigenic centre in SCA12; however, the characteristic hand tremor action and the association of head tremor, voice tremulousness and late development of gait ataxia along with radiological findings (white matter changes in the cerebellum and diffuse brain atrophy), bring it more closely towards FXTAS or essential tremor phenotypically. The presence of extrapyramidal and pyramidal features, however, allow for distinction from essential tremor and FXTAS.
Conclusively, we present the observed typical clinical behaviour of intermediate length of PPP2R2BB-CAG towards SCA12 phenotype with large variability in the age at onset. Overall, 43 CAG repeats can be considered as the shortest CAG length towards SCA12 pathogenicity and also as the diagnostic threshold. The diagnostic threshold can still be lower (CAG-40) or even lower size alleles (CAG 36-40) may be pathogenic with reduced or age-dependent disease penetrance. We also emphasize that SCA12 mutation may not be restricted only to a few populations, rather at this locus (SCA12) recurrence of mutation will be the case in different geographic regions and due to stable nature of CAG repeats larger pathogenic mutation length are not observed widely. Among other geographical areas, there may be population level representation of large normal or intermediate alleles of PPP2R2B-CAG and so will be the presence of SCA12 as indicated in previous reports.
